Updated:
Vladimir Coric Family Trust
Vladimir Coric Family Trust is a single family office based in New Haven; the Altss profile covers its classification, headquarters, registration, AUM band,...
Vladimir Coric Family Trust
Vladimir Coric Family Trust is a family office founded in 2013 in Russia. It focuses on investments in the Connecticut region.
General information
Firm type
Single Family Office
Location
Region
North America
Country
United States
City
New Haven
Corporate office
New Haven, CT, United States
Additional offices
Waltham, MA · Woodbridge, CT
Principals
Vladimir Coric
Settlor / Principal
Sector focus
Frequently asked questions
Who runs investment decisions at the Vladimir Coric Family Trust?
The trust is closely held by Dr. Vladimir Coric, who makes or directs all material investment decisions. There is no publicly named CIO or investment committee, and the office's small footprint across three New England locations suggests a lean decision-making structure supported by external wealth advisors rather than a large internal investment team.
How does the Vladimir Coric Family Trust source its investment opportunities?
The trust does not operate as a proprietary deal-sourcing platform. Its investment activity appears concentrated in public-market securities and direct real estate acquisitions in Connecticut and Massachusetts, likely sourced through private banks, wealth managers, and regional brokers rather than through a dedicated origination team.
Is the trust structured as a single family office or does it take outside capital?
The Vladimir Coric Family Trust is a single family office that manages capital exclusively for the Coric family. There is no evidence of external limited partners, co-investment vehicles, or multi-family-office services offered to other wealthy families.
What is Dr. Coric's ongoing relationship with Biohaven Ltd.?
Dr. Coric remains on the board of Biohaven Ltd., the publicly traded entity that retained the non-migraine neuroscience pipeline following the 2022 Pfizer acquisition. This board seat keeps the family trust indirectly tied to Biohaven Ltd.'s clinical and commercial performance through ongoing equity ownership (per Biohaven corporate governance filings).
Where does the underlying wealth come from?
The family's wealth was generated almost entirely from the October 2022 sale of Biohaven Pharmaceutical Holding Company to Pfizer for roughly $11.6 billion. Dr. Coric was a co-founder, CEO, and Chairman of Biohaven, which developed and commercialized Nurtec ODT, a leading oral CGRP antagonist for migraine.
Does the trust maintain a philanthropic structure?
No separate foundation or donor-advised fund is publicly linked to the Vladimir Coric Family Trust at this time. The trust's investment and giving activities appear to be conducted through the same entity with no formal philanthropic separation visible in public records.
Does the trust invest in biotechnology or healthcare startups?
The trust has not disclosed a formal venture-capital or angel-investing program targeting healthcare startups, despite Dr. Coric's deep biotech operating background. Its known investment activity skews toward diversified public equities and real estate rather than direct private-company biotech exposure, though the family's Biohaven Ltd. holdings maintain indirect pipeline exposure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: